Results from the trial show potential for developing an advanced cell therapy treatment for the condition.
Affecting around two million people globally, MS is a neurodegenerative condition that affects the brain and spinal cord.
Around two-thirds of people with MS will transition into a debilitating secondary progressive phase of the disease within 25 to 30 years of diagnosis.
In a study published in Cell Stem Cell, scientists successfully injected neural stem cells directly into the brains of 15 patients recruited from two hospitals in Italy, with secondary MS.
